Accessibility Menu
Nanobac Pharmaceuticals logo

Nanobac Pharmaceuticals(OTC) NNBP

Current Price$0.00
Market Cap$25.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-50%
1 Year+9,900%
1 Month+9,900%
Nanobac Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-21
Nanobac Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-10
1 month+9,900%USD 0.002026-06-03
3 month+9,900%USD 0.002026-03-20
Year to date+9,900%USD 0.002025-12-31
1 year+9,900%USD 0.002025-03-31
3 year+9,900%USD 0.002023-07-18
5 year-50%USD 0.002021-07-22
Since inception-99.98%USD 0.502003-06-16

Nanobac Pharmaceuticals Financials at a Glance

Market Cap

$25.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$17.62K

Net Income (TTM)

-$6.58M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$0.00

Volume

8,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

NNBP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Incorporated is focused on enhancing human health through innovative products aimed at identifying and managing calcifying nanoparticles (CNPs). The company specializes in in vitro diagnostic (IVD) kits and engages in research for various urological and cardiovascular diseases.

Products and Services
  • In vitro diagnostic (IVD) kits for detecting CNPs
  • NANO-CAPTURE and NANO-SERO diagnostic assays
  • Research and clinical studies on urological and cardiovascular diseases
Growth Outlook
  • Continued focus on expanding diagnostic product offerings
  • Research initiatives targeting chronic prostatitis and kidney stones
  • Potential market growth in cardiovascular disease diagnostics
Financial Highlights
  • Recent quarterly revenue of 4,368, indicating ongoing operations
  • Trailing twelve months (TTM) gross profit margin of 17.6%
  • Operating income margin of 278.9% reflects operational efficiency
Nanobac Pharmaceuticals, Incorporated operates within the biotechnology sector, emphasizing the development of diagnostic tools for health management. The company’s commitment to research and innovation positions it well for future growth, particularly in the areas of urological and cardiovascular health. Recent financial data indicates a focus on operational efficiency, with a notable gross profit margin. The ongoing development of diagnostic products and research initiatives may provide significant opportunities for market expansion.
AI Generated • Jun 27, 2026

Industry

Biotechnology

Headquarters

Tampa, FL 33607, US

NNBP Financials

Key Financial Metrics (TTM)

Gross Margin

17.60%

Operating Margin

27891.78%

Net Income Margin

-37319.74%

Return on Equity

357.99%

Return on Capital

279.30%

Return on Assets

-91.08%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

249.51M

Volume

8.00K

Avg. Volume

1.99K

Financials (TTM)

Gross Profit

$3.10K

Operating Income

$4.92M

EBITDA

-$3.10M

Operating Cash Flow

-$910.89K

Capital Expenditure

-$1.53K

Free Cash Flow

-$912.42K

Cash & ST Invst.

$3.93K

Total Debt

$4.12M

Nanobac Pharmaceuticals Performance Analysis

Nanobac Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12007-03-31114.1%
Q22007-06-30-51.5%
Q32007-09-30138.9%
Q42007-12-31-24.8%
Nanobac Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12007-03-31-74.0%
Q22007-06-3082.4%
Q32007-09-30-17.2%
Q42007-12-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2007YOY CHG

Revenue

$4.37K

+86.6%

Gross Profit

$678.00

-58.7%

Gross Margin

15.52%

N/A

Market Cap

$25.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$25.00K

N/A

Employees

1

N/A

Net Income

-$1.17M

+37.4%

EBITDA

-$1.03M

+40.0%

Quarterly Fundamentals

Name
Q4 2007YOY CHG

Total Cash

$3.93K

-90.0%

Total Debt

$4.12M

-23.2%

Accounts Receivable

$1.87K

+164.0%

Inventory

$10.30K

-84.5%

Long Term Debt

$0.00

N/A

Short Term Debt

$4.12M

-23.2%

Return on Assets

-91.08%

N/A

Return on Invested Capital

10.36%

N/A

Free Cash Flow

-$110.32K

+83.6%

Operating Cash Flow

-$110.32K

+83.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LADXLadRx Corporation
$0.01-89.72%
RBIIRising Biosciences, Inc.
$0.00+0.00%
OWCPOWC Pharmaceutical Research Corp.
$0.00+0.00%
ISOLFIsodiol International Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
AALAmerican Airlines Group
$14.48+0.07%

Questions About NNBP

What is the current price of Nanobac Pharmaceuticals?

Nanobac Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Nanobac Pharmaceuticals?

Over the past 52 weeks, Nanobac Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Nanobac Pharmaceuticals have?

Nanobac Pharmaceuticals total debt is unavailable.

How much cash does Nanobac Pharmaceuticals have on hand?

Nanobac Pharmaceuticals does not have cash on hand data available.

What is Nanobac Pharmaceuticals’s dividend yield?

Nanobac Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.